This content is machine translated Heinz Nixdorf Recall Study When the heart vessels calcify – susceptibility also hereditary An interdisciplinary research team from the Medical Faculty of the University of Duisburg-Essen (UDE) has been able to prove that a person’s lifestyle is not the only factor responsible for…
View Post 2 min This content is machine translated Hypertrophic cardiomyopathies (HCM) Recognize rare causes This training course is all about differential diagnosis and therapy of hypertrophic cardiomyopathies (HCM). First, the previously known etiologies and their respective frequencies are highlighted. The very large group of…
View Post 2 min This content is machine translated Heart failure Current guidelines recommend exercise even for cardiovascular disease Obesity and physical inactivity are two challenges that are becoming more prevalent. Therefore, current guidelines recommend regular exercise not only as a preventative measure against heart disease, but also for…
View Post 5 min This content is machine translated Diabetic nephropathy Gliflozines may slow progression of renal failure Nephropathy as a late complication of diabetes is a common cause of renal failure requiring dialysis. In the CREDENCE trial, SGLT-2 inhibitors slowed the progression of renal dysfunction in diabetic…
View Post 7 min This content is machine translated Atrial fibrillation In practice more and more often Atrial fibrillation is increasing significantly in frequency. However, the symptoms are often not very specific. Therefore, special attention should be paid to risk factors such as hypertension, obesity, and physical…
View Post 12 min This content is machine translated Heart failure Physical training in patients with HFrEF and HFpEF. The increasing prevalence of heart failure is a major medical and economic problem. The number of patients hospitalized for heart failure has been increasing for years. The clinical picture of…
View Post 4 min This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
View Post 4 min This content is machine translated Granulomatous diseases Sarcoidosis – an update for the dermatologist This heterogeneous multisystem disease with immune-mediated pathomechanism has skin involvement in 20-30% of cases, and other organs are affected in 60%. In addition to histological examination, a differential blood count…
View Post 3 min This content is machine translated Renal failure Treat hypertension effectively to protect the kidney There is a reciprocal relationship between elevated blood pressure and kidney disease. Therefore, consistent hypertension therapy is particularly important in the presence of impaired renal performance. This is because intensive…
View Post 2 min This content is machine translated VERTIS-CV Study Evidence base of SGLT-2 inhibitors supplemented by further piece of the mosaic Ertugliflozin as an add-on to standard treatment was shown to be non-inferior to placebo in terms of MACE (major adverse cardiac event) in this large-scale international study. This confirmed the…
View Post 5 min This content is machine translated Heart failure Guideline-based therapy: do’s & don’ts In addition to the groundbreaking new discovery of dapagliflozin as an effective and safe add-on therapy option in heart failure, there are several other interesting updates. Potassium levels are an…
